The US Food and Drug Administration (FDA) has accepted the biologics licence application (BLA) submitted by Eli Lilly for review of its galcanezumab to prevent migraine in adults.

Galcanezumab is a monoclonal antibody being developed to block the activity of calcitonin gene-related peptide (CGRP).

The BLA seeks use of galcanezumab as a self-administered, once-monthly injection using an auto-injector pen or prefilled syringe.

In its application, the firm included positive results from three Phase III clinical trials, EVOLVE-1, EVOLVE-2 and REGAIN, of galcanezumab in a total of 2,901 subjects.

Results indicated a statistically significant reduction in the average number of monthly migraine headache days with galcanezumab treatment when compared to placebo.

“Migraine is more than a headache. It is a debilitating disease affecting one in eight Americans and may cause days of lost productivity each month.”

Injection site reactions were the most common adverse events observed during the trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Eli Lilly Bio-Medicines president Christi Shaw said: “Migraine is more than a headache. It is a debilitating disease affecting one in eight Americans and may cause days of lost productivity each month.

“We have worked for more than 25 years to develop innovative migraine therapies, and we are truly pleased to be one step closer to potentially providing a new self-administered and effective preventive treatment option that may help people experience fewer migraine days.”

Galcanezumab is part of the firm’s investigational, non-opioid pain portfolio that includes lasmiditan for acute treatment of migraine and tanezumab for osteoarthritis, chronic low back pain, and cancer pain.

Earlier this month, Lilly obtained approval from the FDA for its Taltz (ixekizumab) 80mg/mL injection to treat adults with active psoriatic arthritis (PsA).